CRISPR-Based Diagnostics Global Market Report 2026

CRISPR (clustered regularly interspaced short palindromic repeats)-based diagnostics are advanced molecular diagnostic technologies that utilize the CRISPR-Cas system to identify specific nucleic acid sequences rapidly and accurately for the detection of diseases or genetic markers, providing advanced capabilities for medical and genomic analysis. These diagnostic technologies are applied in areas such as infectious disease detection, identification of genetic disorders, and monitoring genetic mutations in cancer research and treatment, while also offering increasing opportunities for personalized medicine and point-of-care diagnostic testing.

The primary products of CRISPR-based diagnostics are kits, buffer solutions, software, and others. Kits used in CRISPR-based diagnostics are ready-to-use solutions developed for the rapid and accurate identification of specific genetic material through CRISPR technology, with applications in disease diagnosis and research. The techniques used include recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), and others. These diagnostics are applied to diseases including infectious diseases and non-infectious diseases and are utilized by hospitals, diagnostic centers, biotechnology companies, academic and research institutions, and others.

Tariffs are influencing the crispr-based diagnostics market by increasing the costs of imported diagnostic kits, enzymes, buffers, reagents, and analytical instruments. Hospitals and diagnostic centers in North America and Europe are particularly affected because of their reliance on imported consumables, while Asia-Pacific is experiencing higher costs for establishing diagnostic infrastructure. These tariffs are increasing testing expenses. However, they are also encouraging domestic production of diagnostic kits, local innovation, and greater supply chain resilience.

The CRISPR-based diagnostics market research report is one of a series of new reports from The Business Research Company that provides CRISPR-based diagnostics market statistics, including CRISPR-based diagnostics industry global market size, regional shares, competitors with a CRISPR-based diagnostics market share, detailed CRISPR-based diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR-based diagnostics industry. This CRISPR-based diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The crispr-based diagnostics market size has grown rapidly in recent years. It will grow from $3.71 billion in 2025 to $4.32 billion in 2026 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to the need for rapid and accurate diagnostics, limitations of traditional molecular tests, pandemic-driven demand for diagnostics, advancements in CRISPR detection methods, and academic validation of CRISPR diagnostics.

The crispr-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.83 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to the expansion of decentralized testing approaches, rising demand for early disease detection, increasing adoption of point-of-care diagnostic solutions, growing integration with digital health platforms, and wider use in oncology and genetic screening applications. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic technologies, expansion of point-of-care testing solutions, growing use for infectious disease detection, greater integration of isothermal amplification technologies, and expansion of personalized diagnostic applications.

The growing incidence of infectious diseases is anticipated to support the expansion of the CRISPR-based diagnostics market in the forecast period. Infectious diseases are medical conditions caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which may be transmitted directly or indirectly between individuals through contaminated surfaces, food, water, or vectors such as insects. The incidence of infectious diseases is increasing because of globalization, antimicrobial resistance, climate change, urbanization, population growth, habitat destruction, and limited access to healthcare services. CRISPR-based diagnostics support the detection and management of infectious diseases by enabling rapid and precise identification of pathogens, supporting early diagnosis, prompt treatment, and effective disease containment. For instance, in August 2024, according to data published by the UK Health Security Agency, a UK-based executive agency, England recorded 368 measles cases in 2023, representing an almost sevenfold increase compared with the 53 cases reported in 2022, while the West Midlands and London accounted for 44% and 33% of the cases, respectively. Therefore, the increasing incidence of infectious diseases is contributing to the growth of the CRISPR-based diagnostics market.

Leading companies operating in the CRISPR-based diagnostics market are focusing on developing strategic partnerships to enhance accessibility to rapid and accurate diagnostics through CRISPR-based point-of-care tests. A strategic partnership is a long-term collaboration between two or more organizations that share resources and expertise to achieve mutual goals and strengthen their competitive advantage. For example, in August 2023, CrisprBits Private Limited, an India-based biotechnology company, announced a strategic collaboration with Molbio Diagnostics, an India-based molecular diagnostics company, to develop CRISPR-based Point-of-Care Tests (POCTs). This collaboration focuses on creating rapid, precise, and cost-effective diagnostic tools leveraging CRISPR technology for detecting pathogens and genetic markers. These POCTs aim to enhance diagnostic accessibility in diverse settings, including resource-limited areas, while ensuring swift and accurate disease detection. The partnership combines CrisprBits' expertise in CRISPR-based platforms with Molbio's manufacturing and distribution capabilities to bring these tests to the global market.

In February 2024, Ginkgo Bioworks Holdings Inc., a US-based biotechnology company, acquired Proof Diagnostics Inc. for an undisclosed amount. Through this acquisition, Ginkgo aimed to strengthen its gene therapy services by incorporating Proof Diagnostics' OMEGA RNA-programmable nuclease technology and advancing its gene editing capabilities. The acquisition enhances Ginkgo's ability to provide sophisticated solutions for therapeutic development and precision gene editing. Proof Diagnostics Inc. is a US-based biotechnology company that develops advanced CRISPR-based molecular testing solutions for COVID-19.

Major companies operating in the crispr-based diagnostics market are Thermo Fisher Scientific Inc., Integrated DNA Technologies Inc., Molbio Diagnostics, Horizon Discovery, Synthego Corporation, Caribou Biosciences, Mammoth Biosciences, Epic Bio, VedaBio, CrisprBits, SNIPR BIOME ApS, TOLO Biotech, Intact Genomics, Agdia Inc., ToolGen Inc., Caspr Biotech, GenScript, Twist Bioscience, Revvity Discovery Limited, Danaher Corporation, Scope Biosciences, CRISPR Diagnostics, Gene Editing Institute, Aptitude Medical Systems, Qiagen, Abingdon Health

North America was the largest region in the CRISPR-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr-based diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the crispr-based diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR-based diagnostics market includes revenues earned by entities by providing services such as diagnostic testing services, custom CRISPR assays development, screening and surveillance services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR-based diagnostics market also consists of sales of CRISPR-based RNA detection systems, CRISPR-based monitoring tools, lateral flow assays, and CRISPR-based test platforms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CRISPR-Based Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses crispr-based diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for crispr-based diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The crispr-based diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Kits; Buffer Solutions; Software; Other Products
• 2) By Technique: Recombinase Polymerase Amplification (RPA); Loop-Mediated Isothermal Amplification (LAMP); Other Techniques
• 3) By Disease: Infectious Diseases; Non-Infectious Diseases
• 4) By End-User: Hospitals; Diagnostic Centers; Biotechnology Companies; Academic And Research Institutes; Other End-Users
• Subsegments:
• 1) By Kits: CRISPR Detection Kits; CRISPR Amplification Kits; CRISPR-Based Assay Kits
• 2) By Buffer Solutions: CRISPR Reaction Buffers; CRISPR Lysis Buffers
• 3) By Software: CRISPR Data Analysis Software; CRISPR Design Software; CRISPR Diagnostic Platforms Software
• 4) By Other Products: CRISPR Enzymes; CRISPR Reagents; CRISPR-Based Probes
• Companies Mentioned: Thermo Fisher Scientific Inc.; Integrated DNA Technologies Inc.; Molbio Diagnostics; Horizon Discovery; Synthego Corporation; Caribou Biosciences; Mammoth Biosciences; Epic Bio; VedaBio; CrisprBits; SNIPR BIOME ApS; TOLO Biotech; Intact Genomics; Agdia Inc.; ToolGen Inc.; Caspr Biotech; GenScript; Twist Bioscience; Revvity Discovery Limited; Danaher Corporation; Scope Biosciences; CRISPR Diagnostics; Gene Editing Institute; Aptitude Medical Systems; Qiagen; Abingdon Health
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.